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he Beginning of the End
r the End of the Beginning?*
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eripheral artery disease (PAD) remains common among
he adult population. Depending on the methods for detec-
ion, the estimated prevalence of PAD among U.S. adults
anges from 2.5% in patients 60 years of age to 18.8% in
atients 70 years of age (1,2). Using the Rose Claudica-
ion Questionnaire, which can underestimate lower extrem-
ty PAD (3), the age-specific annual incidence of intermit-
ent claudication in the Framingham Heart Study ranged
rom 6 per 10,000 men and 3 per 10,000 women for ages 30
o 44 years and increased to 61 per 10,000 men and 54 per
0,000 women for ages 65 to 74 years (4). Overall, an
stimated 8 million Americans have PAD, and it remains
nderdiagnosed. In a large cross-sectional study of patients
rom 350 large-volume primary care practices in 25 Amer-
can cities, among patients age 70 years or older, or patients
0 to 69 years of age who smoked or had diabetes mellitus,
he prevalence of PAD was 19% (5). Within this group,
6% were observed to have both lower extremity PAD and
t least 1 other form of atherosclerotic disease such as
oronary artery disease. Despite the high prevalence of PAD
n this cohort, the diagnosis of PAD was new in 55% of
atients with PAD alone, and new in 33% of patients with
oth lower extremity PAD and cardiovascular disease.
See page 2105
In addition to diabetes, hypertension, and hypercholes-
erolemia, cigarette smoking is a significant risk factor for
AD (3). In fact, smoking is a stronger predictor of PAD
han is coronary artery disease (2). Among patients with
AD, an estimated 80% report currently smoking or have
een a smoker (6,7). Risk of PAD among smokers is 3 to 6
imes higher than among nonsmokers. Among the almost
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiovascular Medicine, Department of Internal Medicine,a
niversity of Michigan Health System, Ann Arbor, Michigan. The authors have
eported that they have no relationships to disclose.,000 participants in the PARTNERS (PAD Awareness,
isk and Treatment: New Resources for Survival) study, the
revalence of tobacco use among subjects with PAD was
7% for current smokers and 37% for former smokers (5).
PAD is associated with significant morbidity and mor-
ality (8). An ankle-brachial index (ABI) 0.90 adds
ndependent prognostic value to the Framingham Risk
core in prediction of 10-year mortality (9). An ABI 0.90
s associated with double the risk of total mortality (9)! A
ecline in ABI of 0.15 over a 10-year period is associated
ith a 2.4 increased risk of total mortality and a 2.8
ncreased risk for cardiovascular mortality (10).
Although smoking rates have declined significantly over
he past several decades, an estimated 23% of men and 18%
f women in the U.S. are current smokers (8). Increased use
f smoking bans in the workplace and community have
ontributed to the decline in smoking. Structured smoking
essation programs have demonstrated success in assisting
mokers to quit. Current guidelines recommend a combi-
ation of behavioral intervention together with the use of
harmacological products for smoking cessation (11). A
eta-analysis of successful smoking cessation intervention
tudies suggests that factors associated with success included
ace-to-face counseling, advice from both providers and
onphysician counselors, and the number of sessions, with
ore being better (12). These aspects are key components
f the randomized clinical trial conducted by Hennrikus et
l. (13) in this issue of the Journal.
Hennrikus et al. (13) reports a randomized trial using a
moking cessation program for patients with PAD. Patients
ith documented PAD who were identified as current
mokers were eligible for the study. Of the 687 outpatients
ontacted, 124 were enrolled. Subjects were randomly as-
igned to an intensive intervention consisting of physician
dvice to quit smoking in addition to smoking cessation
reatment. Treatment included both behavioral and phar-
acological components. Behavioral components included
ethods found effective in prior trials, including selection of
quit date and behavioral and cognitive strategies for coping
ith urges to smoke. Use of pharmacologic agents was
ncouraged. Information on types of pharmacologic projects
sed for smoking cessation was provided; however, subjects
ere instructed to obtain these products through their
ealth insurance and/or healthcare provider, as opposed to
eing offered through the study. In addition, an added
omponent of the intervention was the identification of a
erson from the subject’s social network who was contacted
y the study counselor (by telephone) to discuss smoking
essation strategies as they pertained to that particular
ubject. A total of 6 counseling sessions were planned over
5-month period; however, more sessions could be at-
ended. The comparative arm of this randomized clinical
rial received a minimal intervention defined as receipt of
erbal advice from their vascular provider to quit smoking
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or. The investigators found participants in the intensive
ntervention arm were receptive to the counseling sessions
nd had higher rates of abstinence at 6 month as compared
o the minimal intervention group (21.3% vs. 6.8%; p 
.02).
The investigators are to be congratulated for the comple-
ion of a clinically relevant, detailed study. Their results
uggest intensive counseling support together with provider
dvice and pharmacological smoking cessation products can
ssist smokers to quit. However, this study highlights the
otential difficulty of translating interventions tested in a
esearch venue to the real-world setting; namely, is this a
ost-effective intervention? For many practitioners and pa-
ients with PAD, the cost in time and resources to provide
nd receive intensive counseling sessions is prohibitive. In
ddition, currently many smoking cessation products are not
overed by insurance; thus, smokers are often reluctant to
ay out-of-pocket for such products.
For smoking cessation programs to reach the mainstream
f current therapeutics, several areas are in need of further
nderstanding. First, it is likely that smokers vary in their
eeds during the quitting process (15). What components of
ntensive programs work the best and for which smokers?
urrent guidelines suggest that a combination of behavioral
ntervention with pharmacologic assistance is most success-
ul (11). The research present by Hennrikus et al. (13)
upports this concept. Heavy smokers may also benefit more
rom structured programs (15); this current study included
mokers who averaged at least a pack of cigarettes per day,
nd 90% starting smoking soon after waking. In addition,
he study population was predominately male.
Data from a real-world sample of U.S. adults, the Adult
se of Tobacco Survey, suggests a significant number of
mokers attempt to quit without using a structured program
15). Among smokers who attempted to quit over a 10-year
eriod, 47.5% of smokers who attempted to quit on their
wn were successful, compared with 23.6% of smokers who
sed a cessation program. The 23.6% success rate of those
ho used a structured program in this report is consistent
ith the efficacy of other formal cessation programs that
efine success as 1 year of smoking cessation. Thus, for
any smokers, an intensive program may not be preferable
r feasible. Hennrikus et al. (13) did find subjects randomly
llocated to the intensive intervention arm attended a
ignificant number of sessions, suggesting excellent accep-
ance of the multiple counseling sessions. The overall 20%
uit rate at 6 months for the intensive intervention program
ikely translates into an even lower quit rate at 12 months,
learly a limited effect of the intervention.
Given the logistical and financial difficulties in creating an
ntensive program in practice, exploring other interventions
uch as social media and on-line programs to supplement
ace-to-face counseling is warranted. In addition, providing
harmacologic products free or at reduced cost is likely to
ssist in quit rates. These aspects of smoking cessation
K
crograms have to be addressed before the widespread
ranslation of intensive intervention to the community.
mong populations such as patients with PAD, the high
ates of cardiovascular disease and the resulting morbidity
nd mortality suggest the worth of continued research in the
rea of smoking cessation. However, our idea that one size
ts all is both naïve and also biologically implausible.
eprint requests and correspondence: Dr. Kim A. Eagle, Uni-
ersity of Michigan Cardiovascular Center, 1500 East Medical
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